Ironwood late-breaker oral presentation at digestive disease week® reinforces potential of once-weekly apraglutide for adults with short bowel syndrome with intestinal failure (sbs-if)

Boston--(business wire)--ironwood pharmaceuticals, inc. (nasdaq: irwd), a gi-focused healthcare company, will present late-breaking data during the 2024 digestive disease week® (ddw) meeting from its pivotal phase iii clinical trial, stars, which evaluated the efficacy and safety of once-weekly subcutaneous apraglutide in adult patients with short bowel syndrome with intestinal failure (sbs-if). these findings build on the positive topline data that ironwood previously announced in february 202.
SBS Ratings Summary
SBS Quant Ranking